BICTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE
Pre-LaunchANDATABLET
Lifecycle
Pre-Launch
Clinical Trials
1
Data completeness
2/8 — Basic
BICTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE by Cipla is (bic), emtricitabine (ftc), and tenofovir alafenamide (taf) [see ] .
Drug data last refreshed 19h ago
Mechanism of Action
(BIC), emtricitabine (FTC), and tenofovir alafenamide (TAF) [see ] .
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE
Started Mar 2026
200 enrolled
HIV -1 InfectionHIV (Human Immunodeficiency Virus)HIV+1 more
Company
Cipla
Worked on BICTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE at Cipla? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.